Professor Paulo E. Stanga
Practises Ophthalmology and leads R&D in the independent sector as Consultant Ophthalmologist & Vitreoretinal Surgeon at London Vision Clinic & Spire Manchester Hospital and at Univ. of Manchester.
Professor of Ophthalmology & Retinal Regeneration (Univ. of Manchester).
Previous 21 years NHS experience and over 29 years of experience in Ophthalmology.
Former Consultant Ophthalmologist & Vitreoretinal Surgeon, Manchester Royal Eye Hospital.
Founder and former Director of Manchester Vision Regeneration (MVR) Lab at NIHR Manchester CRF and its Clinical, Surgical and Research Fellowship Program. The MVR Lab focused on Innovation, developing new diagnostic and treatment devices & techniques.
Since 1993, has worked in the development/application of new outpatient and surgical therapies & technologies. Principal Investigator (PI) on industry-sponsored trials and Scientific Advisor to commercial companies that develop pharmacological/surgical therapies, diagnostic/therapeutic equipment.
Introduced: OCT into clinical setting (UK, 1998), Pascal® Laser (Intl. 2006), Swept-Source OCT (EU, 2012) and Hypersonic Vitrectomy (Intl. 2012-19).
Pioneered: Optos® Ultra Wide-Field Imaging (Intl., 2006).
Developed: new Hypersonic Vitrectomy technology from lab bench (2012) to FDA 510(k) clearance, First in Human (2017) and EU introduction (2018).
Current research interests: Ultra-widefield retinal imaging, Swept Source OCT, laser-tissue interaction and treatment techniques in Age-related Macular Degeneration (AMD) and Diabetic Retinopathy and Maculopathy, development of hypersonic vitrectomy, electronic retinal implants/artificial vision and gene therapy in AMD.
Had set-up and was PI for a Manchester-only Pilot Study of the Argus II in Age-Related Macular Degeneration (AMD). Successfully implanted first ever electronic retinal implants in AMD as part of a trial.
Pivotal role for NHS England to fund & evaluate Argus II in advanced Retinitis Pigmentosa: 1st use of Artificial Vision in the NHS (2016).
Performed first Argus II implantations in Retinitis Pigmentosa in several countries helping set up artificial vision programs with which he continues to collaborate; i.e. Russia.
Former UK CI and Manchester PI and Surgeon Gene Therapy Study in Retinitis Pigmentosa (RPGR). Prof. Stanga is the first and only surgeon to have performed Retinal Gene Therapy outside London and Oxford. The National Institute for Health Research (NIHR) England has hailed the start of gene therapy surgery at MREH a Historical Achievement for the city of Manchester.
Current research interests: vitreo-retinal imaging, laser-tissue interaction, laser photocoagulation techniques, development of hypersonic vitrectomy, electronic retinal implants/artificial vision and gene therapy.
Received several international accolades, amongst others, the prestigious Achievement Award/American Academy of Ophthalmology (AAO).
Prof. Stanga specialises in vitreo-retinal disorders that require either medical, laser or surgical treatment, ocular trauma and cataract surgery.